ANIMAL CELL TECHONOLOGY COURSE 2013
Date:

September 29 - October 3, 2013

Location:

The course will be held in Hotel Terramar, a three star hotel (www.hterramar.com) in a small town named Llafranc in the heart of Costa Brava, Girona, Spain. The hotel is right on a very nice sandy beach, providing a cozy and relaxing atmosphere for the participants. Weather in Llafranc at this time of the year is generally pleasant.


Outline:

After the interest received by the 1st and 2nd edition and the excellent feed-back from the attendants, the 3rd edition of the ACT course will be organised by the ESACT (European Society of Animal Cell Technology) in Llafranc, Costa Brava/Spain, from 29th September to 3rd October 2013. ESACT is presenting this activity as one more contribution to the community involved in the use of animal cells in Biotechnology and Biomedicine.

The Course is planned in an intensive four day schedule, with a number of participants limited to a maximum of 30, in order to facilitate the interaction among them and with the lecturers. Lecturers will stay for most of the Course duration. The Course comprises lectures covering the main topics of Animal Cell Technology:

  1. Cell line development
  2. Cellular mechanisms
  3. Post-translational modifications
  4. Bioreactor design
  5. Downstream processing
  6. Genomics and proteomics
  7. Bioreactor scale-up and scale-down. Single use bioreactors
  8. Process Analytical Technology
  9. Economical aspects of ACT bioprocesses
  10. Integrated bioprocess for protein production
  11. Integrated bioprocess for stem cells

The program has slots dedicated to the preparation and presentation of case studies by participants, and discussion groups with the lecturers.

Organizers:

Paula Alves (IBET, Portugal) and Francesc Gòdia (UAB, Spain)

Lecturers:

Terry Papoutsakis (University Delaware, USA), Manuel Carrondo (IBET, Portugal), Hansjörg Hauser (HZI, Germany), Ana Teixeira (IBET, Portugal), Francesc Gòdia (UAB, Spain), Paula Alves (IBET, Portugal) and Anne Tolstrup (Boehringer Ingelheim Pharma, Germany)

Newsletter
Insert your email to receive our newsletter